Table 3

Baseline plasma copeptin and requirement of lower-extremity revascularization during follow-up in the cohorts with type 2 diabetes

HR95% CIP
Crude1.441.26–1.63<0.0001
Model 11.301.13–1.490.0002
Model 21.201.03–1.390.02
  • HR computed by Cox proportional hazards survival regression analysis for 1 SD of log[copeptin]. Model 1: adjustment for cohort membership; sex; age; duration of diabetes; BMI; arterial hypertension; diastolic blood pressure; total cholesterol; HDL cholesterol; current tobacco smoking; use of insulin, ACE inhibitors, angiotensin receptor blockers, diuretics, blood pressure–lowering drugs, or antiplatelet or anticoagulation drugs; and previous history of myocardial infarction, stroke, or LEA at baseline. Model 2: model 1 adjustments plus adjustment for eGFR and UAC at baseline. P < 0.05 is significant.